ESCO Technologies Inc. (ESE)
Technology · Scientific & Technical Instruments · NYSE
ESCO Technologies Inc. revenue & earnings — last 10 fiscal years
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $571.46M | $685.74M | $771.58M | $726.04M | $730.47M | $715.44M | $857.50M | $956.03M | $1.03B | $1.10B |
| Gross profit | $220.65M | $248.82M | $351.87M | $288.05M | $272.16M | $270.39M | $332.05M | $453.35M | $496.20M | $461.08M |
| Net income | $45.88M | $53.70M | $92.14M | $81.04M | $99.41M | $63.50M | $82.32M | $92.55M | $101.88M | $299.22M |
| Net margin | 8.0% | 7.8% | 11.9% | 11.2% | 13.6% | 8.9% | 9.6% | 9.7% | 9.9% | 27.3% |
Source: ESCO Technologies Inc. SEC filings (10-K). 18 years of history available in the interactive view.
Explore 18 years of ESCO Technologies Inc. financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track ESE in your portfolio →
About ESCO Technologies Inc.
ESCO Technologies Inc. provides engineered components and systems for aviation, navy, defense, and industrial customers. The Aerospace & Defense segment designs and manufactures specialty filtration products, including hydraulic filter elements and fluid control devices used in commercial and defense aerospace applications; miniature electro-explosive devices for military aircraft ejection seats and missile arming devices; manufactures and sells mission-critical bushings, pins, sleeves, and precision-tolerance machined components for landing gear, rotor heads, engine mounts, flight controls, and actuation systems for the aerospace and defense industries; designs, develops and manufactures elastomeric-based signature reduction solutions for U.S. naval vessels; and provides mission-critical signature and power management solutions. The Utility Solutions Group segment develops, manufactures, and delivers diagnostic testing solutions; and designs and manufactures decision support tools for the renewable energy industry, primarily wind and solar. The RF Test & Measurement segment designs and manufactures products and systems to measure and control RF energy for research and development, regulatory compliance, and medical and security applications; and turnkey systems, such as RF test facilities and measurement systems, acoustic test enclosures, RF and magnetically shielded rooms, and secure communication facilities. This segment also supplies RF absorptive materials, filters, antennas, field probes, test cells, proprietary measurement software, and other test accessories; and offers calibration and product tests, feedthrough capacitors, high current power, telephone, data and control line filters, and high-altitude electromagnetic protection filters. It distributes its products through distributors, sales representatives, direct sales teams, and in-house sales personnel. The company was incorporated in 1990 and is based in Saint Louis, Missouri.
ESCO Technologies Inc. — frequently asked questions
What is ESCO Technologies Inc.'s revenue?
ESCO Technologies Inc. (ESE) reported revenue of $1.10B for fiscal year 2025, up 6.7% from the prior year, according to its SEC filings.
Is ESCO Technologies Inc. profitable?
Yes. ESE earned net income of $299.22M in fiscal 2025, a net margin of 27.3%.
What is ESE's P/E ratio?
ESCO Technologies Inc. trades at a price-to-earnings ratio of about 60.5 based on the latest data in our nightly-refreshed cache.
How fast is ESCO Technologies Inc. growing?
ESE's revenue grew at roughly 8.4% per year over the last five fiscal years (compound annual growth rate), computed from SEC-filed statements.
Where does this data come from?
All figures are computed from ESCO Technologies Inc.'s official SEC filings (10-K and 10-Q), covering 18 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.